Mark Craven is a professor in the Department of Biostatistics and Medical Informatics at the University of Wisconsin, and an affiliate faculty member in the Department of Computer Sciences. He is the Director of the Center for Predictive Computational Phenotyping, one of the NIH Centers of Excellence for Big Data Computing. He is also the Director of the NIH/NLM-funded Computation and Informatics in Biology and Medicine (CIBM) Training Program, and a member of the Institute for Clinical and Translational Research, the Carbone Cancer Center, and the Genome Center of Wisconsin. The focus of his research program is on developing and applying machine-learning methods to infer models of, and reason about, networks of interactions among genes, proteins, clinical and environmental factors, and phenotypes of interest.
Dr. Huang is an Associate Professor at the Department of Experimental and Clinical Pharmacology, University of Minnesota. She is also an Associate Director for the Institute of Personalized Medicine | Pharmacogenomics U of M Alliance (PUMA-IPM) and a member of the Masonic Cancer Center at the University of Minnesota. She is a member of American Association for Cancer Research (AACR), American Society of Human Genetics (ASHG), and American Society of Clinical Pharmacology and Therapeutics (ASCPT). To date, she has published over 70 original research papers many of which are in high caliber journals, e.g., Nature, Nature Medicine, PNAS, Blood, Cancer Research, Genome Biology and American Journal of Human Genetics. Dr. Huang is a board certified clinical pharmacologist with extensive training in genetics, molecular and cell biology, clinical trials and high throughput data analysis.
The Huang laboratory’s main research focus is translational pharmacogenomics with particular interest in the pharmacogenomics of anti-cancer agents. By systematically evaluating human genome and its relationships to drug response and toxicity, their goal is to develop clinically useful models that predict risks for adverse drug reactions and non-response prior to administration of chemotherapy. With her broad training background, Dr. Huang assembles and leads a multi-disciplinary team that consists of computational biologist, geneticist, pharmacist, physician, molecular biologist and biostatistician to tackle a series of serious problems in cancer research. These include the lack of mechanistic understanding of genomic regulation of cancer phenotypes; the lack of reproducible predictive biomarkers for cancer therapeutic agents; and the lack of effective treatment for many hard to treat cancers.
More information about the Huang lab can be found online at http://huang-lab.umn.edu/
Dr. Christine Vogel is a trained biochemist with a Master's in Mathematical Biology and a PhD in Computational Structural Biology obtained from the University of Cambridge, with Drs. Cyrus Chothia and Sarah Teichmann. After post-doctoral work with Dr. Edward Marcotte (Univ. of Texas at Austin), she joined New York University as faculty in 2011. Her lab uses a combination of proteomics, transcriptomics, computational, and targeted approaches to investigate the regulation of protein expression under stress. Her work was recognized by the US Human Proteomics Organization with the 2017 Robert J. Cotter New Investigator Award.